UK Markets open in 6 hrs 38 mins

Mereo BioPharma Group plc (MREO)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
2.0600+0.0100 (+0.49%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close2.0500
Open2.1000
Bid2.0000 x 3200
Ask2.0900 x 1400
Day's range1.9900 - 2.1395
52-week range1.7300 - 4.7110
Volume893,913
Avg. volume802,036
Market cap222.985M
Beta (5Y monthly)1.49
PE ratio (TTM)N/A
EPS (TTM)-3.3670
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est677.90
  • Globe Newswire

    Mereo BioPharma to Present at Two Upcoming Investor Conferences

    LONDON and REDWOOD CITY, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer of Mereo, will present at two upcoming investor conferences: Jefferies London Healthcare ConferenceIn-person Fireside Chat, Wednesday, November 17 at 10:00 a.m. Greenwich Mean Time Piper Sandler 33rd Annual Virtu

  • Globe Newswire

    Data from Investigator-sponsored Trial of Mereo BioPharma’s alvelestat in Bronchiolitis Obliterans Syndrome (BOS) Accepted for Presentation at American Society of Hematology (ASH) Annual Meeting

    LONDON and REDWOOD CITY, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical stage biopharmaceutical company focused on oncology and rare diseases, today announced that data from an investigator-sponsored study of alvelestat in patients with Bronchiolitis Obliterans Syndrome (“BOS”) following hematopoietic stem cell transplantation (“HCT”) will be shared in a poster presentation at the 2021 American Society of Hematology (ASH)

  • Motley Fool

    2 Growth Stocks That Could Deliver 1,000% Returns

    Thanks to the ongoing innovation revolutions in both the tech and healthcare sectors, shareholders have been enjoying historic returns on capital over the past decade. For example, the central nervous system disorder drug specialist Axsome Therapeutics, the cancer specialist Exelixis, and the electric car pioneer Tesla have all delivered tenfold returns for investors who bought these names at their low points. Which stocks might be the next Axsome, Exelixis, or Tesla from a growth standpoint?